Neurobehavioral effects of interferon-α in patients with hepatitis-C: Symptom dimensions and responsiveness to paroxetine

Neuropsychopharmacology

Volumn 37, Issue 6, 2012, Pages 1444-1454

  McNutt, Marcia D ^a   Liu, Shuling ^b   Manatunga, Amita ^b   Royster, Erica B ^c   Raison, Charles L ^d,e   Woolwine, Bobbi J ^d,e   Demetrashvili, Marina F ^d,e   Miller, Andrew H ^d,e   Musselman, Dominique L ^f  

^a Department of Biology   (United States)

^b EMORY UNIVERSITY   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

depressive; hepatitis C; interferon a; neurovegetative; paroxetine; ribavirin

Indexed keywords

ALBINTERFERON ALPHA2B; PAROXETINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; ZOLPIDEM;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; AUTONOMIC NEUROPATHY; CANCER PATIENT; CLINICAL ASSESSMENT; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEUROPSYCHIATRY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MOOD DISORDERS; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862779106     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.330     Document Type: Article

References (85)

1. Ambermoon P, Carter A, Hall WD, Dissanayaka NN, O'Sullivan JD (2011). Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction 106: 283-293.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders: DSM-IV 4th edn American Psychiatric Association: Washington, DC.
3. Auyeung SF, Long Q, Royster EB, Murthy S, McNutt MD, Lawson DH et al (2009). Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy. Clin Trials 6: 480-490.
4. Bagaglio S, Cinque P, Racca S, Pedale R, Grasso MA, Lazzarin A et al (2005). Hepatitis C virus populations in the plasma, peripheral blood mononuclear cells and cerebrospinal fluid of HIV/hepatitis C virus-co-infected patients. AIDS 19(Suppl 3): S151-S165. (Pubitemid 41683151)
5. Bender CM, Ergyn FS, Rosenzweig MQ, Cohen SM, Sereika SM (2005). Symptom clusters in breast cancer across 3 phases of the disease. Cancer Nurs 28: 219-225. (Pubitemid 40734541)
6. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M et al (2002). Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 22: 86-90. (Pubitemid 34101297)
7. Bull SJ, Huezo-Diaz P, Binder EB, Cubells JF, Ranjith G, Maddock C et al (2009). Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 14: 1095-1104.
8. Capuron L, Miller AH (2004). Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 56: 819-824.
9. Capuron L, Ravaud A, Dantzer R (2000). Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 18: 2143-2151. (Pubitemid 30324368)
10. Centers for Disease Control and Prevention (2011). Hepatitis C information for health professionals. http://www.cdc.gov/hepatitis/HCV/index. htm.
11. Chang E, Boyd A, Nelson CC, Crowley D, Law T, Keough KM et al (1997). Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol 19: 237-244. (Pubitemid 27276291)
12. Chen ML, Tseng HC (2006). Symptom clusters in cancer patients. Support Care Cancer 14: 825-830.
13. Constant A, Castera L, Dantzer R, Couzigou P, de Ledinghen V, Demotes-Mainard J et al (2005). Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 66: 1050-1057. (Pubitemid 41191799)
14. DiMatteo MR, Lepper HS, Croghan TW (2000). Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160: 2101-2107. (Pubitemid 30482715)
15. Dodd MJ, Miaskowski C, Paul SM (2001). Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum 28: 465-470.
16. Folstein MF, Folstein SE, McHugh A (1975). 'Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
17. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J et al (2002). Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 35: 433-439. (Pubitemid 34106386)
18. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al (2009). Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature 461: 399-401.
19. Gift AG, Stommel M, Jablonski A, Given W (2003). A cluster of symptoms over time in patients with lung cancer. Nurs Res 52: 393-400.
20. Giosue S, Casarini M, Ameglio F, Zangrilli P, Palla M, Altieri AM et al (2000). Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur Cytokine Netw 11: 99-104.
21. Guillemin GJ, Wang L, Brew BJ (2005). Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. J Neuroinflammation 2: 16.
22. Hammond MF (1998). Rating depression severity in the elderly physically ill patient: reliability and factor structure of the Hamilton and the Montgomery-Asberg depression rating scales. Int J Geriatr Psychiatry 13: 257-261. (Pubitemid 28192680)
23. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J et al (2002). A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 7: 942-947. (Pubitemid 35333048)
24. Haward LR (1979). Multivariate symptom analysis related to response to lorazepam treatment. Curr Med Res Opin 6: 20-23. (Pubitemid 9162750)
25. Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E (2001). Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol 96: 157-164. (Pubitemid 32104824)
26. Horikawa N, Yamazaki T, Sagawa M, Nagata T (1999). A case of akathisia during interferon-alpha therapy for chronic hepatitis type C. Gen Hosp Psychiatry 21: 134-135. (Pubitemid 29200436)
27. Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H (2000). Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 54: 565-572.
28. Kamata M, Higuchi H, Yoshimoto M, Yoshida K, Shimizu T (2000). Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol 10: 129-132. (Pubitemid 30120043)
29. Kearns NP, Cruickshank CA, McGuigan KJ, Riley SA, Shaw SP, Snaith RP (1982). A comparison of depression rating scales. Br J Psychiatry 141: 45-49. (Pubitemid 12074468)
30. Kelley KW, Bluthe RM, Dantzer R, Zhou JH, Shen WH, Johnson RW et al (2003). Cytokine-induced sickness behavior. Brain Behav Immun 17(Suppl 1): S112-S118. (Pubitemid 36298523)
31. Khan A, Brodhead AE, Kolts RL (2004). Relative sensitivity of the Montgomery-Asberg depression rating scale, the Hamilton depression rating scale and the clinical global impressions rating scale in antidepressant clinical trials: a replication analysis. Int Clin Psychopharmacol 19: 157-160. (Pubitemid 38586487)
32. Kim HJ, McGuire DB, Tulman L, Barsevick AM (2005). Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs 28: 270-282.
33. Kirkova J, Walsh D (2007). Cancer symptom clustersFa dynamic construct. Support Care Cancer 15: 1011-1013. (Pubitemid 47340974)
34. Kirkova J, Walsh D, Aktas A, Davis MP (2010). Cancer symptom clusters: old concept but new data. Am J Hosp Palliat Care 27: 282-288.
35. Kraus MR, Schafer A, Csef H, Faller H, Mork H, Scheurlen M (2001). Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Dig Dis Sci 46: 2060-2065. (Pubitemid 32955211)
36. Kumai T, Tateishi T, Tanaka M, Watanabe M, Shimizu H, Kobayashi S (2000). Effect of interferon-alpha on tyrosine hydroxylase and catecholamine levels in the brain of rats. Life Sci 67: 663-669. (Pubitemid 30451905)
37. Lang CA, Conrad S, Garrett L, Battistutta D, Cooksley WG, Dunne MP et al (2006). Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. J Pain Symptom Manage 31: 335-344.
38. Laskus T, Radkowski M, Bednarska A, Wilkinson J, Adair D, Nowicki M et al (2002). Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol 76: 10064-10068. (Pubitemid 35006549)
39. Lindsay KL (1997). Therapy of hepatitis C: overview. Hepatology 26(3 Suppl 1): 71S-77S. (Pubitemid 27388076)
40. Loftis JM, Huckans M, Ruimy S, Hinrichs DJ, Hauser P (2008). Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci Lett 430: 264-268.
41. Lotrich FE, Loftis JM, Ferrell RE, Rabinovitz M, Hauser P (2011). IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. J Interferon Cytokine Res 31: 331-336.
42. Maggi F, Giorgi M, Fornai C, Morrica A, Vatteroni ML, Pistello M et al (1999). Detection and quasispecies analysis of hepatitis C virus in the cerebrospinal fluid of infected patients. J Neurovirol 5: 319-323. (Pubitemid 29329107)
43. Mahrer AR, Mason DJ, Rosenshine M (1966). A headache syndrome in psychiatric patients: symptom clusters accompanying headaches. J Clin Psychol 22: 411-414.
44. Manesis EK, Hadziyannis SJ (2001). Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 121: 101-109. (Pubitemid 32591519)
45. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485-1492. (Pubitemid 28543496)
46. Miaskowski C, Dodd M, Lee K (2004). Symptom clusters: the new frontier in symptom management research. J Natl Cancer Inst Monogr 32: 17-21.
47. Miller AH (2009). Norman cousins lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav Immun 23: 149-158.
48. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389. (Pubitemid 9136500)
49. Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B et al (2010). Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebocontrolled trial. Psychosomatics 51: 401-408.
50. Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P (2007). A randomized trial of paroxetine to prevent interferonalpha-induced depression in patients with hepatitis C. J Affect Disord 103: 83-90. (Pubitemid 47445756)
51. Morsica G, Bernardi MT, Novati R, Uberti Foppa C, Castagna A, Lazzarin A (1997). Detection of hepatitis C virus genomic sequences in the cerebrospinal fluid of HIV-infected patients. J Med Virol 53: 252-254. (Pubitemid 28201834)
52. Murray J, Fishman SL, Ryan E, Eng FJ, Walewski JL, Branch AD et al (2008). Clinicopathologic correlates of hepatitis C virus in brain: a pilot study. J Neurovirol 14: 17-27. (Pubitemid 351314970)
53. O'Connor JC, Lawson MA, Andre C, Moreau M, Lestage J, Castanon N et al (2009). Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 14: 511-522.
54. Oxenkrug G, Perianayagam M, Mikolich D, Requintina P, Shick L, Ruthazer R et al (2011). Interferon-gamma (+874) T/A genotypes and risk of IFN-alpha-induced depression. J Neural Transm 118: 271-274.
55. Pemberton LA, Kerr SJ, Smythe G, Brew BJ (1997). Quinolinic acid production by macrophages stimulated with IFN-gamma, TNFalpha, and IFN-alpha. J Interferon Cytokine Res 17: 589-595. (Pubitemid 27451155)
56. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al (1998). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks vs interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352: 1426-1432. (Pubitemid 28510876)
57. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM et al (2005a). Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 66: 41-48.
58. Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ et al (2005b). Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 19: 23-27. (Pubitemid 39592806)
59. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G et al (2010). CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 15: 393-403.
60. Raison CL, Woolwine BJ, Demetrashvili MF, Borisov AS, Weinreib R, Staab JP et al (2007). Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Alimentary Pharm Therapeutics 25: 1163-1174. (Pubitemid 46650303)
61. Rubin DB (1976). Inference and missing data. Biometrika 63: 581-592.
62. Schaefer M, Schwaiger M, Pich M, Lieb K, Heinz A (2003). Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry 36(Suppl 3): S203-S206. (Pubitemid 38085138)
63. Serretti A, Mandelli L (2010). Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 71: 1259-1272.
64. Seyam MS, Freshwater DA, O'Donnell K, Mutimer DJ (2005). Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C*. J Viral Hepat 12: 531-535. (Pubitemid 41224259)
65. Shuto H, Kataoka Y, Horikawa T, Fujihara N, Oishi R (1997). Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 747: 348-351. (Pubitemid 27077413)
66. Su KP, Huang SY, Peng CY, Lai HC, Huang CL, Chen YC et al (2010). Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol Psychiatry 67: 550-557.
67. Sunami M, Nishikawa T, Yorogi A, Shimoda M (2000). Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha. Clin Neuropharmacol 23: 59-61. (Pubitemid 30090415)
68. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU (1991). Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 114: 532-538.
69. Teva Pharmaceuticals USA Inc. (2011). Paroxetine. http://www.drugs.com/ pro/paroxetine.html.
70. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P (1998). Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 25(Suppl 1): 39-47. (Pubitemid 28093154)
71. Vargas HE, Laskus T, Radkowski M, Wilkinson J, Balan V, Douglas DD et al (2002). Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation. Liver Transpl 8: 1014-1019. (Pubitemid 35363627)
72. Vecsei L, Beal MF (1990). Influence of kynurenine treatment on open-field activity, elevated plus-maze, avoidance behaviors and seizures in rats. Pharmacol Biochem Behav 37: 71-76. (Pubitemid 20341688)
73. Walsh D, Donnelly S, Rybicki L (2000). The symptoms of advanced cancer: relationship to age, gender, and performance status in 1000 patients. Support Care Cancer 8: 175-179. (Pubitemid 30183032)
74. Walsh D, Rybicki L (2006). Symptom clustering in advanced cancer. Support Care Cancer 14: 831-836. (Pubitemid 44060996)
75. Wang XS, Fairclough DL, Liao Z, Komaki R, Chang JY, Mobley GM et al (2006). Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol 24: 4485-4491. (Pubitemid 46630988)
76. Weissenborn K, Ennen JC, Bokemeyer M, Ahl B, Wurster U, Tillmann H et al (2006). Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 55: 1624-1630. (Pubitemid 44629214)
77. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S (2003). Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29: 241-252. (Pubitemid 37069655)
78. Wichers MC, Koek GH, Robaeys G, Praamstra AJ, Maes M (2005). Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes. Psychol Med 35: 433-441. (Pubitemid 40372481)
79. Wilkie MJ, Smith G, Day RK, Matthews K, Smith D, Blackwood D et al (2009). Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J 9: 61-70.
80. Williams GW, Barton GM, White AA, Won H (1976). Cluster analysis applied to symptom ratings of psychiatric patients: an evaluation of its predictive ability. Br J Psychiatry 129: 178-185.
81. Yates WR, Gleason O (1998). Hepatitis C and depression. Depress Anxiety 7: 188-193. (Pubitemid 28368579)
82. Yonkers KA, Samson J (2000). Mood disorders measures. In: Rush AJ, Pincus HA, First MB, et al (eds) Handbook of Psychiatric Measures. American Psychiatric Association: Washington, DC. pp 515-549.
83. Yoon JC, Crane PK, Ciechanowski PS, Harrington RD, Kitahata MM, Crane HM (2011). Somatic symptoms and the association between hepatitis C infection and depression in HIV-infected patients. AIDS Care 23: 1208-1218.
84. Yoshida K, Alagbe O, Wang X, Woolwine B, Thornbury M, Raison CL et al (2005). Promoter polymorphisms of the interferonalpha receptor gene and development of interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings. Neuropsychobiology 52: 55-61. (Pubitemid 41160320)
85. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM (2000). Hepatitis C, interferon alfa, and depression. Hepatology 31: 1207-1211. (Pubitemid 30351279)